Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19541914 | 0.93 | PNMT (0.51) | PNMTTAS1R3TAS1R1EPHX1MEN1 | |
| SCHEMBL21124992 | 0.90 | EPHX1 (0.48) | PNMTTAS1R3TAS1R1EPHX1MEN1 | |
| SCHEMBL13951834 | 0.90 | PNMT (0.54) | PNMTMEN1ALDH1A1CYP1A2POLB | |
| SCHEMBL21868754 | 0.88 | PNMT (0.44) | PNMTTAS1R3TAS1R1EPHX1MEN1 | |
| SCHEMBL18885429 | 0.88 | PNMT (0.44) | PNMTTAS1R3TAS1R1EPHX1MEN1 | |
| SCHEMBL18885350 | 0.87 | EPHX1 (0.48) | PNMTTAS1R3TAS1R1EPHX1MEN1 | |
| SCHEMBL22357736 | 0.85 | GRIA4 (0.38) | PNMTTAS1R3TAS1R1EPHX1ALDH1A1 | |
| SCHEMBL21129503 | 0.84 | PNMT (0.44) | PNMTTAS1R3TAS1R1EPHX1MEN1 | |
| SCHEMBL12384049 | 0.84 | TAAR1 (0.51) | PNMTEPHX1CYP1A2CYP3A4IDO1 | |
| SCHEMBL18593507 | 0.83 | PNMT (0.53) | PNMTMEN1ALDH1A1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230159537-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | TIANJIN JIKUN MEDICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-01-07 | — | — | US | disclosed |
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-12-31 | — | — | US | disclosed |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10421751-B2 | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | ICHAN SCHOOL OF MEDICINE AT MOUNT SINAL (US) | 2019-07-04 | — | — | US | disclosed |
| US-10266560-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180111922-A1 | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE | LYCERA CORPORATION | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519113-B2 | Kinase inhibitor compounds, compositions, and methods of treating cancer | MAP3K1, KSR1, MAP3K11 | PNMT 4168/4885TAS1R3 2033/4885TAS1R1 2019/4885 |
| US-10398706-B2 | Heteroaryldiazepine derivatives as RSV inhibitors | CYP3A5, CYP3A43, CYP3A4 | PNMT 932/4885TAS1R3 4498/4885TAS1R1 4410/4885 |
| US-20180111922-A1 | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATEMENT OF DISEASE | RORB, RORA, RORC | PNMT 4800/4885TAS1R3 3031/4885TAS1R1 2180/4885 |
| US-20190202789-A1 | KINASE INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING CANCER | MAP3K1, KSR1, MAP3K11 | PNMT 4168/4885TAS1R3 2033/4885TAS1R1 2019/4885 |
| US-20230159537-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | FGFR1, FGFR3, FGFR4 | PNMT 4061/4885TAS1R3 1308/4885TAS1R1 2094/4885 |
| US-20210002253-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | PNMT 4001/4885TAS1R3 4460/4885TAS1R1 4517/4885 |
| US-10266560-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | PNMT 4565/4885TAS1R3 129/4885TAS1R1 124/4885 |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | PNMT 4011/4885TAS1R3 721/4885TAS1R1 785/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | PNMT 4001/4885TAS1R3 4460/4885TAS1R1 4517/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | PNMT 107/4885TAS1R3 2452/4885TAS1R1 1374/4885 |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | PNMT 4001/4885TAS1R3 4460/4885TAS1R1 4517/4885 |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | PNMT 4011/4885TAS1R3 721/4885TAS1R1 785/4885 |
| US-10421751-B2 | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | PNMT 4836/4885TAS1R3 3029/4885TAS1R1 2343/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | PNMT 4001/4885TAS1R3 4460/4885TAS1R1 4517/4885 |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | PNMT 3586/4885TAS1R3 1094/4885TAS1R1 1175/4885 |
| US-20180193352-A1 | HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS | CYP3A5, CYP3A43, CYP3A4 | PNMT 932/4885TAS1R3 4498/4885TAS1R1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.